| Title: | A systematic review of the diagnostic accuracy of volatile organic compounds in airway diseases and their relation to markers of type-2 inflammation |
| Author(s): | Ibrahim W; Natarajan S; Wilde M; Cordell R; Monks PS; Greening N; Brightling CE; Evans R; Siddiqui S; |
| Address: | "Leicester NIHR Biomedical Research Centre (Respiratory Theme), Glenfield Hospital, Leicester, UK. Dept of Respiratory Sciences, College of Life Sciences, University of Leicester, Leicester, UK. These authors contributed equally. Dept of Chemistry, University of Leicester, Leicester, UK. See Acknowledgements for contributors" |
| DOI: | 10.1183/23120541.00030-2021 |
| ISSN/ISBN: | 2312-0541 (Print) 2312-0541 (Electronic) 2312-0541 (Linking) |
| Abstract: | "BACKGROUND: Asthma and COPD continue to cause considerable diagnostic and treatment stratification challenges. Volatile organic compounds (VOCs) have been proposed as feasible diagnostic and monitoring biomarkers in airway diseases. AIMS: To 1) conduct a systematic review evaluating the diagnostic accuracy of VOCs in diagnosing airway diseases; 2) understand the relationship between reported VOCs and biomarkers of type-2 inflammation; 3) assess the standardisation of reporting according to STARD and TRIPOD criteria; 4) review current methods of breath sampling and analysis. METHODS: A PRISMA-oriented systematic search was conducted (January 1997 to December 2020). Search terms included: 'asthma', 'volatile organic compound(s)', 'VOC' and 'COPD'. Two independent reviewers examined the extracted titles against review objectives. RESULTS: 44 full-text papers were included; 40/44 studies were cross-sectional and four studies were interventional in design; 17/44 studies used sensor-array technologies (e.g. eNose). Cross-study comparison was not possible across identified studies due to the heterogeneity in design. The commonest airway diseases differentiating VOCs belonged to carbonyl-containing classes (i.e. aldehydes, esters and ketones) and hydrocarbons (i.e. alkanes and alkenes). Although individual markers that are associated with clinical biomarkers of type-2 inflammation were recognised (i.e. ethane and 3,7-dimethylnonane for asthma and alpha-methylstyrene and decane for COPD), these were not consistently identified across studies. Only 3/44 reported following STARD or TRIPOD criteria for diagnostic accuracy and multivariate reporting, respectively. CONCLUSIONS: Breath VOCs show promise as diagnostic biomarkers of airway diseases and for type-2 inflammation profiling. However, future studies should focus on transparent reporting of diagnostic accuracy and multivariate models and continue to focus on chemical identification of volatile metabolites" |
| Notes: | "PubMed-not-MEDLINEIbrahim, Wadah Natarajan, Sushiladevi Wilde, Michael Cordell, Rebecca Monks, Paul S Greening, Neil Brightling, Christopher E Evans, Rachael Siddiqui, Salman eng England 2021/09/04 ERJ Open Res. 2021 Aug 31; 7(3):00030-2021. doi: 10.1183/23120541.00030-2021. eCollection 2021 Jul" |
